Latest News in the pharma Industry

Research & Development

Zymeworks and Innovative Targeting Solutions enter collaboration and license agreement to advance biotherapeutics R&D

Zymeworks and Innovative Targeting Solutions enter collaboration and license agreement to advance biotherapeutics R&D

13 Aug 2016

Collaboration will use HuTARG - a first-in-class protein engineering platform.

Read more 
Arch Biopartners engages Catalent to begin manufacturing process for AB569

Arch Biopartners engages Catalent to begin manufacturing process for AB569

13 Aug 2016

Preparations underway for the first human trials involving patients with antibiotic resistant lung infections.

Read more 
Lilly to continue trial of abemaciclib and fulvestrant combo for breast cancer

Lilly to continue trial of abemaciclib and fulvestrant combo for breast cancer

11 Aug 2016

Following interim analysis, a DMC recommends the study to continue without modification.

Read more 
ADDC and AstraZeneca announce third year of screening partnership

ADDC and AstraZeneca announce third year of screening partnership

10 Aug 2016

Partnership facilitates efforts by researchers from academia to discover novel compounds with the potential to become new patient treatments.

Read more 
Veritas reaches important scientific milestone

Veritas reaches important scientific milestone

10 Aug 2016

Animal studies fully underway to evaluate the safety and effectiveness of cannabis strains.

Read more 
University of Pittsburgh licenses novel microneedle patch to SkinJect

University of Pittsburgh licenses novel microneedle patch to SkinJect

9 Aug 2016

SkinJect Microneedle Patch to deliver drug to treat and immunize skin cancer patients.

Read more 
Charles River Laboratories announces partnership with the Milner Therapeutics Institute and Consortium

Charles River Laboratories announces partnership with the Milner Therapeutics Institute and Consortium

9 Aug 2016

Through this partnership, the academic institutions in the Consortium will have access to Charles River’s early discovery and drug development resources and services to accelerate their early-stage drug development processes.

Read more 
FDA approves Merck’s Keytruda for patients with recurrent or metastatic HNSCC

FDA approves Merck’s Keytruda for patients with recurrent or metastatic HNSCC

7 Aug 2016

New treatment option for patients with with disease progression on or after platinum-containing chemotherapy.

Read more 
BMS CheckMate -26 trial fails to meet primary endpoint

BMS CheckMate -26 trial fails to meet primary endpoint

7 Aug 2016

Opdivo did not meet trial primary endpoint of progression-free survival in patients expressing PD-L1 ≥ 5%.

Read more 
Regeneron and Adicet Bio collaborate to discover and develop next-generation engineered immune cell therapeutics

Regeneron and Adicet Bio collaborate to discover and develop next-generation engineered immune cell therapeutics

3 Aug 2016

Companies to pursue "off-the-shelf" cellular therapies in oncology.

Read more 
Catalent Biologics and Zumutor collaborate to develop antibodies with enhanced ADCC Activity

Catalent Biologics and Zumutor collaborate to develop antibodies with enhanced ADCC Activity

2 Aug 2016

The partnership created a fucose knockout GPEx cell line expressing high levels of an anti-HER2 antibody.

Read more 
Selecta Biosciences describes novel approach for improving the efficacy and safety profile of biologic drugs

Selecta Biosciences describes novel approach for improving the efficacy and safety profile of biologic drugs

1 Aug 2016

The data support Selecta’s lead clinical program, showing Selecta’s SVP-Rapamycin (SEL-110) induces antigen-specific immune tolerance and prevents the formation of anti-drug antibodies to biologic drugs, including pegsiticase (for gout) and adalimumab ...

Read more